Aura Biosciences, Inc. is a clinical-stage biotechnology company. Co. is engaged in developing precision immunotherapies to treat solid tumors designed to preserve the function of the afflicted organ with cancer. It is developing a pipeline of virus-like drug conjugates (VDCs), a class of drugs with a dual mechanism of action, that promote cancer cell death by both the delivery of the cytotoxic payload to generate acute necrosis and activation of a secondary immune mediated response. We show 13 historical shares outstanding datapoints in our AURA shares outstanding history coverage, used to compute AURA market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing AURA market cap history over the course of time is important for investors
interested in comparing AURA's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of AURA versus a peer is one thing; comparing
AURA market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like AURA can fluctuate over the course of history.
With this page we aim to empower investors researching AURA by allowing them to research the AURA market cap history. |
Free AURA Email Alerts:
Video: The Importance of Market Cap
